Research programme: myostatin inhibitors - MYOS Corporation

Drug Profile

Research programme: myostatin inhibitors - MYOS Corporation

Latest Information Update: 31 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cloud Pharmaceuticals; MYOS Corporation
  • Class Small molecules
  • Mechanism of Action Furin modulators; Janus kinase 3 inhibitors; Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cachexia; Muscular atrophy

Most Recent Events

  • 17 Jul 2014 MYOS Corporation and Cloud Pharmaceuticals enter into a research and development agreement for myostatin inhibitors in USA for Muscular atrophy and Cachexia
  • 17 Jul 2014 Early research in Cachexia in USA (unspecified route)
  • 17 Jul 2014 Early research in Muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top